Cost of NMN Supplements in 2026: Prices, Compounded Rapamycin, and Insurance Reality

What Does NMN Actually Cost in 2026?

Retail NMN supplements range from $40 to $120 per month in 2026, with price driven primarily by dose, formulation, and brand reputation. A 500 mg daily regimen from a well-tested third-party-verified brand typically lands between $55 and $80 per month, while liposomal formulations targeting improved bioavailability can push that figure past $100.

NMN (nicotinamide mononucleotide) is a precursor to NAD+, the coenzyme that powers mitochondrial energy transfer and is central to DNA repair pathways studied by researchers including David Sinclair's group at Harvard. NAD+ levels decline with age, falling roughly 50% between age 40 and age 60 in human tissue samples measured in published research. [1]

Several factors determine the final price you pay each month.

Dose. Most published human trials used 250 mg to 500 mg daily. A 2022 randomized controlled trial (N=30) published in npj Aging found that 250 mg daily NMN for 12 weeks raised blood NAD+ levels significantly compared to placebo, though functional endpoints like grip strength and walking speed showed only modest trends. [2] Brands selling 1 to 000 mg or higher daily doses charge proportionally more and currently lack dose-specific outcome data in humans to justify the premium.

Formulation type. Standard capsules are cheapest. Sublingual tablets and liposomal suspensions cost 20% to 40% more per milligram, with manufacturers citing first-pass metabolism bypass as the rationale. Head-to-head bioavailability data in humans for these NMN delivery formats remain sparse as of early 2026.

Third-party testing status. Products verified by NSF International, USP, or Informed Sport carry a 10% to 25% price premium over unverified competitors. Given that the FDA classifies NMN as a dietary supplement under 21 CFR Part 111, manufacturing quality controls are far less stringent than pharmaceutical standards, making third-party certification the most meaningful quality signal available to buyers. [3]

Subscription vs. one-time purchase. Auto-ship programs from direct-to-consumer brands typically reduce monthly cost by 15% to 20% compared to single-bottle retail pricing.

A practical monthly cost breakdown at current 2026 market prices:

• 250 mg/day, standard capsule, unverified brand: approximately $40 to $55
• 500 mg/day, standard capsule, NSF-certified brand: approximately $65 to $90
• 500 mg/day, liposomal or sublingual, NSF-certified: approximately $95 to $120
• 1 to 000 mg/day, standard capsule: approximately $100 to $160

No Medicare, Medicaid, or private insurance plan currently reimburses NMN for any indication, because it lacks FDA drug approval.

NMN vs. NR: Is the Price Difference Worth It?

NR (nicotinamide riboside) averages $30 to $80 per month and converts to NAD+ through a different enzymatic pathway than NMN. The cost gap is real.

A 2023 crossover pharmacokinetic study (N=12) published in Nature Communications found that both NMN and NR raised whole-blood NAD+ levels within two hours of oral ingestion, with no statistically significant difference in peak NAD+ increase between equal molar doses. [4] NMN proponents argue that a specific transporter (Slc12a8) allows direct cellular uptake without conversion, though this transporter's relevance in human gut tissue remains debated as of 2026. [5]

From a strict cost-per-NAD+-unit-raised perspective, NR is the more affordable option for most people. The clinical decision between them depends less on price and more on individual response and any concurrent prescriptions, because NR and NMN share downstream metabolism with niacin and can interact with certain medications affecting methylation pathways.

How Much Does Compounded Rapamycin Cost?

Compounded rapamycin for longevity-directed dosing costs $80 to $250 per month in 2026, depending on dose and the specific compounding pharmacy. Most longevity-oriented clinicians prescribe 3 mg to 6 mg once weekly, a regimen popularized by physician and author Peter Attia and studied in the Interventions Testing Program (ITP) at the National Institute on Aging. [6]

Brand-name Rapamune (sirolimus) tablets carry a list price of roughly $3,200 for 100 tablets of 1 mg strength, making a 5 mg weekly dose cost approximately $670 per month at retail without insurance. Compounded sirolimus from a 503A or 503B pharmacy bypasses that pricing entirely, which is why the compounding route dominates longevity prescribing.

Price variation across compounding pharmacies reflects several real differences.

503A vs. 503B status. A 503A pharmacy compounds for individual patients with a valid prescription. A 503B outsourcing facility can produce larger batches under stricter FDA oversight, generally resulting in more consistent product quality but not necessarily lower price. [7]

Dose strength. Compounded capsules at 1 mg each are cheaper per capsule than 5 mg capsules because 1 mg sirolimus compounding requires less active pharmaceutical ingredient per unit, though the monthly cost for an equivalent weekly dose ends up similar or slightly higher due to dispensing fees on multiple capsules.

Geographic and telehealth platform variation. Longevity telehealth platforms that partner with affiliated compounding pharmacies typically bundle the prescribing visit ($100 to $200 one-time or annual) with ongoing pharmacy pricing. Some platforms offer $99 per month all-in for a 5 mg weekly dose. Others charge $150 to $250 per month for the same dose at pharmacies with tighter quality assurance documentation.

The table below summarizes 2026 compounded rapamycin pricing tiers by dose:

| Weekly dose | Estimated monthly cost (compounded) | Notes | |---|---|---| | 2 mg | $80 to $110 | Starting dose in most longevity protocols | | 3 mg | $90 to $130 | Common maintenance dose | | 5 mg | $110 to $175 | Upper end of typical longevity range | | 6 mg | $140 to $250 | Requires closer monitoring of trough levels |

Trough blood levels (sirolimus target <3 ng/mL for longevity use) require periodic labs, adding $40 to $90 per draw depending on whether your clinician orders a standard sirolimus immunoassay through a reference lab.

Does Insurance Cover Rapamycin for Longevity or Anti-Aging?

No standard insurance plan covers rapamycin when prescribed for longevity, anti-aging, or any off-label indication in 2026. Coverage exists only for its FDA-approved indications: organ transplant rejection prophylaxis and the treatment of certain lymphangioleiomyomatosis (LAM) cases. [8]

The legal framework matters here. The FDA does not prohibit physicians from prescribing approved drugs off-label. The agency stated this directly in a 2018 guidance document: "Once a product has been approved for one use, physicians may prescribe it for other uses that are not approved. This practice is known as 'off-label' prescribing." [9] What the FDA does restrict is manufacturer promotion of off-label uses, which is why Pfizer (the maker of Rapamune) cannot market sirolimus for longevity even as clinicians prescribe it for that purpose.

Insurance coverage, however, follows a different logic than prescribing legality. Insurers reimburse based on ICD-10 diagnostic codes and whether a drug has approval or a strong coverage policy for that diagnosis. Off-label longevity prescribing carries no ICD-10 code that triggers coverage. Submitting a claim under a false diagnosis to obtain reimbursement constitutes insurance fraud.

HSA and FSA accounts occupy a middle ground. A prescription for rapamycin from a licensed physician is required, but having that prescription does not automatically make the medication HSA-eligible. IRS Publication 502 specifies that expenses for "illegal operations or treatments" and for treatments "merely beneficial to general health" are not deductible. [10] A Letter of Medical Necessity from your prescribing physician arguing a specific medical indication may support HSA reimbursement in some cases, but the outcome is plan-dependent and not guaranteed.

What Off-Label Longevity Drugs Might Insurance Cover Indirectly?

A small number of off-label longevity-adjacent prescriptions do receive insurance reimbursement through on-label indications.

Metformin. Generic metformin costs $4 to $15 per month at major pharmacy chains for a 500 mg twice-daily dose. Insurance covers metformin universally for type 2 diabetes. For patients with prediabetes (fasting glucose 100 to 125 mg/dL), coverage depends on the insurer's specific policy. The TAME Trial (Targeting Aging with Metformin, N=3,000, ongoing through 2025 to 2026) is the first clinical trial formally designed to test a drug against biological aging as a primary endpoint; results are expected in late 2026. [11]

Low-dose naltrexone. Compounded LDN (1.5 mg to 4.5 mg nightly) costs $30 to $60 per month at compounding pharmacies. Insurance does not cover compounded formulations. Standard naltrexone tablets (50 mg, FDA-approved for opioid and alcohol use disorder) can be prescribed and covered on-label, but the 50 mg dose is not used in the low-dose longevity protocol.

GLP-1 receptor agonists. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) carry significant evidence for reducing cardiovascular events and all-cause mortality risk in high-risk populations, giving them partial overlap with longevity-focused prescribing goals. Brand-name Wegovy has a list price of $1,349 per month without insurance, but manufacturer savings cards can reduce that to $0 for commercially insured patients with an obesity diagnosis. Compounded semaglutide from 503B pharmacies remained available through early 2026 during periods of documented shortage, typically priced at $150 to $300 per month.

How to Reduce Out-of-Pocket Costs for Longevity Compounds

Several concrete strategies reduce monthly spending on longevity compounds that insurance will not cover.

Buy in bulk with third-party verification. NMN purchased in 3-month or 6-month supplies from NSF-certified brands typically costs 15% to 25% less per dose than monthly repurchase. Confirm that the batch certificate of analysis is accessible on the brand's website before committing to a large order.

Use a longevity-specialized telehealth platform. Platforms that prescribe compounded rapamycin, metformin, or low-dose naltrexone often have negotiated pharmacy pricing that beats retail compounding pharmacy quotes by $30 to $70 per month. Platforms typically charge $99 to $200 per year for the prescribing relationship, which pays for itself within one to two months compared to fee-for-service compounding pharmacy pricing.

Maximize HSA contributions before age 65. In 2026, the IRS HSA contribution limit is $4,300 for individual coverage and $8,550 for family coverage. Pre-tax dollars spent on qualifying prescription medications reduce the effective after-tax cost of any prescription rapamycin or compounded medication that a physician has documented as medically necessary.

Request a sirolimus generic when available. Generic sirolimus tablets (not compounded) are available at several retail pharmacies at significantly lower prices than Rapamune. GoodRx pricing for generic sirolimus 1 mg tablets at major chain pharmacies runs approximately $180 to $400 for a 30-tablet supply in early 2026, depending on location and pharmacy. For a 5 mg weekly dose, that equates to roughly $25 to $55 per month, which undercuts most compounding pharmacy prices if your prescriber is comfortable with tablet formulation and your insurance does not cover the cost.

Check manufacturer patient assistance programs. These programs apply only to branded FDA-approved drugs, not compounded medications or supplements. For patients with documented low income, Pfizer's Rapamune Patient Assistance Program covers the full cost of brand-name sirolimus when insurance is absent or inadequate.

The Real Evidence Gap for NMN in Humans

Pricing discussions for NMN need honest calibration against the actual human trial data. The evidence base is thin.

The most cited human study, a 2022 RCT published in npj Aging (N=30, ages 65 and older), showed that 250 mg oral NMN for 12 weeks raised blood NAD+ levels by approximately 40% compared to baseline, with no serious adverse events. [2] Walking speed, grip strength, and fatigue scores trended positively but did not reach statistical significance at P<0.05. A second trial (N=25) from Keio University School of Medicine found no improvement in insulin sensitivity or physical performance with 250 mg NMN over 10 weeks in healthy older men. [12]

Rodent data are more extensive. NMN supplementation reversed age-related decline in physical activity and metabolic function in C57BL/6 mice in a landmark 2013 Cell Metabolism paper by Yoshino et al. [1] Translating mouse data to human dosing is not straightforward: mice metabolize NMN at rates roughly 7 to 10 times faster per unit of body mass than humans.

The honest summary: the human data do not yet confirm that NMN produces the outcomes seen in mice at doses people can afford. Paying $100 per month for 1 to 000 mg daily NMN is getting ahead of the evidence. The $50 to $65 range for a 500 mg daily dose from a tested brand reflects a reasonable speculative investment if a physician has reviewed your individual health context.

Rapamycin Safety Considerations That Affect Dosing Cost

Dosing decisions directly affect monthly cost, so safety context matters. Rapamycin is an mTORC1 inhibitor. Chronic daily dosing at transplant-level doses (2 mg to 5 mg daily) produces well-documented immunosuppression, impaired wound healing, hyperlipidemia, and oral ulcers. [13]

The longevity dosing rationale uses weekly or every-other-week pulse dosing specifically to avoid steady-state immunosuppression. A 2022 study published in eLife (N=180 healthy volunteers aged 55 to 79) found that 5 mg weekly rapamycin for 8 weeks improved vaccine immune response compared to placebo, a finding that contradicts the assumption that any rapamycin use suppresses immunity at low weekly doses. [14] That study used 5 mg weekly, placing it in the middle of the $110 to $175 monthly compounded cost range.

Side effects requiring dose reduction (and therefore cost reduction) include mouth sores, acne-like rash, and transient LDL elevation. Clinicians monitoring patients on weekly rapamycin typically check a lipid panel and complete metabolic panel at 3-month intervals, adding $60 to $150 per year in lab costs to the total program expense.

Insurance Coverage for Off-Label Use: The Full Picture

Insurance coverage for off-label prescriptions is less uniformly denied than most patients assume. The key variables are drug type, diagnosis code, and plan type.

Medicare Part D. Medicare covers off-label drug use only when supported by one of several recognized drug compendia (Micromedex, Lexi-Drugs, the AHFSDrug Information monograph), or when the FDA has approved the use. Longevity and anti-aging indications appear in none of these compendia as of 2026. Medicare will not cover rapamycin for longevity. [15]

Commercial insurance. A 2019 analysis published in JAMA Internal Medicine (N=2.1 million insurance claims) found that 21% of all drug prescriptions written in the outpatient setting were off-label, and that only 27% of off-label prescriptions had strong scientific evidence supporting them. Insurers denied off-label claims at a much higher rate when evidence strength was low. [16] For a drug like rapamycin used for longevity, where no Phase III RCT in humans for that specific indication exists, denial rates are essentially 100%.

Prior authorization appeals. Patients and clinicians can appeal insurance denials with peer-reviewed literature. The success rate for off-label appeals varies widely. A letter from your prescribing physician citing the eLife 2022 rapamycin vaccine study or the TAME Trial rationale for metformin may persuade some commercial plans to cover metformin for prediabetes, which is a much more defensible claim than rapamycin for longevity. Appeals are worth filing for metformin at prediabetes HbA1c levels between 5.7% and 6.4%.

Employer self-funded plans. Self-funded ERISA plans set their own formularies and can choose to cover off-label uses. A small number of progressive employers offering executive health or longevity benefits have added compounded rapamycin or NMN to health benefit allowances. These are not insurance reimbursements but rather employer health stipends, typically $50 to $200 per month as a taxable fringe benefit.

The FDA's off-label prescribing guidance states clearly: "Good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics, and devices according to their best knowledge and judgment." [9] That statement protects prescribers. It does not obligate payers.